(Press-News.org) PHILADELPHIA, PA (December 28, 2011)—Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic Oncology Group (GOG) showed that a targeted therapy called bevacizumab (Avastin) effectively delayed the progression of advanced ovarian cancer. Patients with newly diagnosed advanced ovarian cancer now typically undergo surgery and chemotherapy, but the new research suggests an additional avenue of treatment. The results of the trial appear in the December 29 issue of the New England Journal of Medicine.
"This approach can be looked upon as a third major component of treatment for ovarian cancer and related malignancies," says Robert A. Burger, MD, lead investigator on the GOG study and director of the Women's Cancer Center at Fox Chase Cancer Center. "We've had the combination of surgical management and cytotoxic chemotherapy for many years, but we haven't really seen anything else in terms of a fundamental class of treatment. This represents a new way for us to control the disease."
The placebo-controlled study, which was sponsored by the National Cancer Institute, enrolled 1,873 patients with previously untreated advanced disease from 336 sites, primarily in the United States, but also in Canada, South Korea, and Japan. The patients either had stage III ovarian cancer that could not be entirely removed with surgery, or stage IV disease, and were randomly assigned to one of three groups. For patients who received bevacizumab with chemotherapy followed by bevacizumab for up to an additional 10 months, the median time until their cancer progressed was 14.1 months, compared to 10.3 months for patients in the control group, who received chemotherapy with a placebo and then continued with a placebo. The net effect was a 28% reduction in the risk of disease of ovarian cancer progression over time. Patients who received bevacizumab only with chemotherapy, but not afterward, had a median progression-free survival of 11.2 months.
The National Cancer Institute estimates that nearly 22,000 women were diagnosed with ovarian cancer in 2011, and more than 15,000 died of the disease. For patients diagnosed before the cancer has spread, the five-year relative survival rate is about 93 percent (relative survival measures survival of cancer only, independent of other causes of death). But ovarian cancer is insidious—early symptoms, like bloating, abdominal pain, and trouble eating, are typical of many illnesses and easily dismissed as non-threatening. Women often do not learn they have the disease until it's already spread. In 62 percent of new cases, the patient's cancer has metastasized to distant sites, and the five-year survival rate is just under 27 percent.
Bevacizumab is already FDA-approved for use against some types of colon, lung, kidney and brain cancers; its accelerated approval for metastatic breast cancer was recently revoked by the FDA. The drug acts by binding with vascular endothelial growth factor (VEGF), a protein produced by certain cancers that helps initiate the growth of new blood vessels that feed the tumor. The process of growing new blood vessels is called angiogenesis, and bevacizumab is an angiogenesis inhibitor.
"Bevacizumab blocks the growth factor VEGF, which is important in the process of ovarian cancer progression," says Burger, "and we've seen that this drug is also active in patients with recurrent disease."
Angiogenesis happens at the interface between the host and the disease, which makes it an appealing target for treatment, says Burger, who also led the Phase II GOG study on using bevacizumab in women with recurrent ovarian cancer. He says different ovarian cancers may appear identical under the microscope but differ biologically, which means they'll respond differently to treatment.
In the NEJM paper, Burger and his co-authors point out that another ovarian cancer trial conducted primarily in Europe called ICON7 demonstrated positive results in using becavizumab in combination with chemotherapy and then continued for up to 7 months.
###
Co-authors on the NEJM paper include Mark F. Brady, Roswell Park Cancer Institute; Michael A. Bookman, Arizona Cancer Center; Gini F. Fleming, University of Chicago; Bradley J. Monk, Creighton University School of Medicine; Helen Huang, Roswell Park; Robert S. Mannel, University of Oklahoma Health Sciences Center, Oklahoma City; Howard D. Homesley, Wake Forest University School of Medicine; Jeffrey Fowler, James Cancer Hospital at the Ohio State University, Hilliard; Benjamin E. Greer, Seattle Cancer Care Alliance; Matthew Boente, Minnesota Oncology and Hematology; Michael J. Birrer, Harvard Medical School and Massachusetts General Hospital; and Sharon X. Liang, North Shore–Long Island Jewish Health System.
Fox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's Web site at www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427).
END
Boston, MA - In March 2011, a surgical team at Brigham and Women's Hospital (BWH) performed the first full face transplantation (FFT) in the United States and went on to complete a total of three FFTs this year. Now, in the first research publication to evaluate FFT in the US, and largest series worldwide, the researchers describe details of patient preparation, novel design and execution of the operation as well as unique immunosuppression protocol allowing for lowest long-term maintenance drug regimen. They also share details of the early functional outcomes and demonstrate ...
With high unemployment and declining household incomes, meeting student loan obligations can be difficult, if not impossible. However, defaulting on federal student loans can have disastrous consequences. The government can garnish wages, withhold tax returns, and place liens on personal property. A default can also affect a person's professional license status. It's important for student loan borrowers to note that a default should be avoided at all costs.
Missing one student loan payment makes a borrower delinquent. Nine months of delinquency puts a borrower in default. ...
In a study of 3.8 million attendees to 249 raves over 12 years, researchers found that almost 27,897 people visited a first aid station, and more than a third (10,100) reported a substance-related problem. Of these, 515 required professional medical care, and 16 cases were life-threatening. Most (66.7%) substance-related problems were associated with ecstasy, alcohol, or both. People using GHB most often required professional medical care, although the authors found no evidence for life-threatening, acute effects of the drug. The study was conducted based on data from ...
Wrong-way auto accidents are exceedingly rare, but when they occur, they often have tragic results. According to the National Highway Traffic Safety Administration (NHTSA), 23 people in Arizona died in car crashes in 2009 (the latest year with available data) when a driver entered a road against traffic or drove on the wrong side of the road.
In addition, in September 2011, two women in a sedan were killed by a man in a pickup truck travelling the wrong way on I-10 in Phoenix. Also, a wrong-way accident shut down the same freeway before Thanksgiving for several hours.
Impaired ...
The microbes on your skin determine how attractive you are to mosquitoes, which may have important implications for malaria transmission and prevention, according to a study published Dec. 28 in the online journal PLoS ONE.
Without bacteria, human sweat is odorless to the human nose, so the microbial communities on the skin play a key role in producing each individual's specific body odor. The researchers, led by Niels Verhulst of Wageningen University in the Netherlands, conducted their experiments with the Anopheles gambiae sensu stricto mosquito, which plays an important ...
ST. PAUL, Minn. – New research links 'silent strokes,' or small spots of dead brain cells, found in about one out of four older adults to memory loss in the elderly. The study is published in the January 3, 2012, print issue of Neurology®, the medical journal of the American Academy of Neurology.
"The new aspect of this study of memory loss in the elderly is that it examines silent strokes and hippocampal shrinkage simultaneously," said study author Adam M. Brickman, PhD, of the Taub Institute for Research on Alzheimer's Disease and the Aging Brain at Columbia University ...
Half the drugs used today target a single class of proteins – and now scientists have identified an important molecular player critical to the proper workings of those proteins critical to our health.
A protein known as Ric-8 plays a vital role, according to new results from a team led by Gregory Tall, Ph.D., assistant professor of Pharmacology and Physiology at the University of Rochester Medical Center. The work was published recently in Science Signaling.
What you see, what you smell, how you feel – molecules known as G-protein coupled receptors and their prime targets, ...
CORVALLIS, Ore. – New research has found that elderly people with higher levels of several vitamins and omega 3 fatty acids in their blood had better performance on mental acuity tests and less of the brain shrinkage typical of Alzheimer's disease – while "junk food" diets produced just the opposite result.
The study was among the first of its type to specifically measure a wide range of blood nutrient levels instead of basing findings on less precise data such as food questionnaires, and found positive effects of high levels of vitamins B, C, D, E and the healthy oils ...
DALLAS – Dec. 22, 2011 – A UT Southwestern Medical Center study using a sophisticated "glass mouse" research model has found that multidrug-resistant tuberculosis (TB) is more likely caused in patients by speedy drug metabolism rather than inconsistent doses, as is widely believed.
If the study published in The Journal of Infectious Diseases is borne out in future investigations, it may lead to better ways to treat one of the world's major infectious diseases. Health workers worldwide currently are required to witness each administration of the combination of drugs during ...
Pregnant women often go to great lengths to provide a healthy environment for their developing babies. From avoiding sushi and alcohol to taking added vitamins and extra vegetables many recommendations abound for pregnant women. These lists can become overwhelming. Experts from the Mayo Clinic agree that some risks are more dangerous than others.
Common Risks Associated with Antidepressant Use During Pregnancy
Research no longer supports the theory that pregnancy protects a woman from depression. Hormones associated with pregnancy may even make coping with depression ...
